Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 5.9% - Time to Sell?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) traded down 5.9% during mid-day trading on Monday . The stock traded as low as $18.55 and last traded at $18.71. 908,187 shares were traded during trading, a decline of 65% from the average session volume of 2,617,507 shares. The stock had previously closed at $19.88.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ARWR shares. Chardan Capital reissued a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. Sanford C. Bernstein reduced their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating on the stock in a research report on Friday, November 29th. Citigroup dropped their target price on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating for the company in a report on Wednesday, November 27th. StockNews.com upgraded Arrowhead Pharmaceuticals to a "sell" rating in a report on Friday, December 20th. Finally, Piper Sandler dropped their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $43.33.

Arrowhead Pharmaceuticals Trading Down 1.2 %

The company has a market cap of $2.53 billion, a PE ratio of -4.03 and a beta of 0.95. The company's 50 day simple moving average is $20.50 and its two-hundred day simple moving average is $21.48. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74.

Insider Buying and Selling

In related news, insider James C. Hamilton sold 32,729 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the transaction, the insider now owns 272,122 shares of the company's stock, valued at approximately $5,393,458.04. This represents a 10.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Patrick O'brien sold 29,184 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $19.82, for a total value of $578,426.88. Following the completion of the transaction, the chief operating officer now directly owns 535,201 shares of the company's stock, valued at approximately $10,607,683.82. This represents a 5.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 147,432 shares of company stock valued at $2,957,986. Company insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ARWR. R Squared Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $38,000. Values First Advisors Inc. acquired a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $52,000. Van ECK Associates Corp increased its holdings in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company's stock valued at $88,000 after purchasing an additional 788 shares in the last quarter. Finally, KBC Group NV boosted its stake in shares of Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after buying an additional 1,644 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.